Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study

Nicola Fossati; Daniele Robesti; R. Jeffrey Karnes; Matteo Soligo; Stephen A. Boorjian; Alberto Bossi; Gabriele Coraggio; Nadia Di Muzio; Cesare Cozzarini; Barbara Noris Chiorda; Giorgio Gandaglia; Simone Scarcella; Detlef Bartkowiak; Dirk Böhmer; Shahrokh Shariat; Gregor Goldner; Antonino Battaglia; Steven Joniau; Karin Haustermans; Gert De Meerleer; Valérie Fonteyne; Piet Ost; Hein Van Poppel; Francesco Montorsi; Thomas Wiegel; Alberto Briganti

doi:10.1016/j.eururo.2019.02.004

Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study

Nicola Fossati, Daniele Robesti, R. Jeffrey Karnes, Matteo Soligo, Stephen A. Boorjian, Alberto Bossi, Gabriele Coraggio, Nadia Di Muzio, Cesare Cozzarini, Barbara Noris Chiorda, Giorgio Gandaglia, Simone Scarcella, Detlef Bartkowiak, Dirk Böhmer, Shahrokh Shariat, Gregor Goldner, Antonino Battaglia, Steven Joniau, Karin Haustermans, Gert De MeerleerValérie Fonteyne, Piet Ost, Hein Van Poppel, Francesco Montorsi, Thomas Wiegel, Alberto Briganti

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

The oncological benefit of hormonal therapy (HT) duration among men receiving salvage radiation therapy for increasing prostate-specific antigen after radical prostatectomy depends on their clinical and pathological characteristics. Our data suggest a significant effect of long-term HT for patients with two or more adverse features. Conversely, short-term HT was sufficient for patients with a single risk factor, whereas patients without any risk factors did not show a significant benefit from concomitant HT.

Original language	English
Pages (from-to)	443-449
Number of pages	7
Journal	European Urology
Volume	76
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2019.02.004
Publication status	Published - Oct 2019

Keywords

Biochemical tumor markers
Hormonal therapy
Neoplasm recurrence
Prostatic neoplasms
Radiotherapy
Salvage therapy

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2019.02.004

Cite this

Fossati, N., Robesti, D., Karnes, R. J., Soligo, M., Boorjian, S. A., Bossi, A., Coraggio, G., Di Muzio, N., Cozzarini, C., Noris Chiorda, B., Gandaglia, G., Scarcella, S., Bartkowiak, D., Böhmer, D., Shariat, S., Goldner, G., Battaglia, A., Joniau, S., Haustermans, K., ... Briganti, A. (2019). Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. European Urology, 76(4), 443-449. https://doi.org/10.1016/j.eururo.2019.02.004

Fossati, N, Robesti, D, Karnes, RJ, Soligo, M, Boorjian, SA, Bossi, A, Coraggio, G, Di Muzio, N , Cozzarini, C, Noris Chiorda, B, Gandaglia, G, Scarcella, S, Bartkowiak, D, Böhmer, D, Shariat, S, Goldner, G, Battaglia, A, Joniau, S, Haustermans, K, De Meerleer, G, Fonteyne, V, Ost, P, Van Poppel, H, Montorsi, F, Wiegel, T & Briganti, A 2019, 'Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study', European Urology, vol. 76, no. 4, pp. 443-449. https://doi.org/10.1016/j.eururo.2019.02.004

@article{4d218b4e97334270941affb8f28b90cd,

title = "Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study",

abstract = "The oncological benefit of hormonal therapy (HT) duration among men receiving salvage radiation therapy for increasing prostate-specific antigen after radical prostatectomy depends on their clinical and pathological characteristics. Our data suggest a significant effect of long-term HT for patients with two or more adverse features. Conversely, short-term HT was sufficient for patients with a single risk factor, whereas patients without any risk factors did not show a significant benefit from concomitant HT.",

keywords = "Biochemical tumor markers, Hormonal therapy, Neoplasm recurrence, Prostatic neoplasms, Radiotherapy, Salvage therapy",

author = "Nicola Fossati and Daniele Robesti and Karnes, {R. Jeffrey} and Matteo Soligo and Boorjian, {Stephen A.} and Alberto Bossi and Gabriele Coraggio and {Di Muzio}, Nadia and Cesare Cozzarini and {Noris Chiorda}, Barbara and Giorgio Gandaglia and Simone Scarcella and Detlef Bartkowiak and Dirk B{\"o}hmer and Shahrokh Shariat and Gregor Goldner and Antonino Battaglia and Steven Joniau and Karin Haustermans and {De Meerleer}, Gert and Val{\'e}rie Fonteyne and Piet Ost and {Van Poppel}, Hein and Francesco Montorsi and Thomas Wiegel and Alberto Briganti",

year = "2019",

month = oct,

doi = "10.1016/j.eururo.2019.02.004",

language = "English",

volume = "76",

pages = "443--449",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy

T2 - Results from a Multi-Institutional Study

AU - Fossati, Nicola

AU - Robesti, Daniele

AU - Karnes, R. Jeffrey

AU - Soligo, Matteo

AU - Boorjian, Stephen A.

AU - Bossi, Alberto

AU - Coraggio, Gabriele

AU - Di Muzio, Nadia

AU - Cozzarini, Cesare

AU - Noris Chiorda, Barbara

AU - Gandaglia, Giorgio

AU - Scarcella, Simone

AU - Bartkowiak, Detlef

AU - Böhmer, Dirk

AU - Shariat, Shahrokh

AU - Goldner, Gregor

AU - Battaglia, Antonino

AU - Joniau, Steven

AU - Haustermans, Karin

AU - De Meerleer, Gert

AU - Fonteyne, Valérie

AU - Ost, Piet

AU - Van Poppel, Hein

AU - Montorsi, Francesco

AU - Wiegel, Thomas

AU - Briganti, Alberto

PY - 2019/10

Y1 - 2019/10

N2 - The oncological benefit of hormonal therapy (HT) duration among men receiving salvage radiation therapy for increasing prostate-specific antigen after radical prostatectomy depends on their clinical and pathological characteristics. Our data suggest a significant effect of long-term HT for patients with two or more adverse features. Conversely, short-term HT was sufficient for patients with a single risk factor, whereas patients without any risk factors did not show a significant benefit from concomitant HT.

AB - The oncological benefit of hormonal therapy (HT) duration among men receiving salvage radiation therapy for increasing prostate-specific antigen after radical prostatectomy depends on their clinical and pathological characteristics. Our data suggest a significant effect of long-term HT for patients with two or more adverse features. Conversely, short-term HT was sufficient for patients with a single risk factor, whereas patients without any risk factors did not show a significant benefit from concomitant HT.

KW - Biochemical tumor markers

KW - Hormonal therapy

KW - Neoplasm recurrence

KW - Prostatic neoplasms

KW - Radiotherapy

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=85062223268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062223268&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2019.02.004

DO - 10.1016/j.eururo.2019.02.004

M3 - Article

C2 - 30799187

AN - SCOPUS:85062223268

SN - 0302-2838

VL - 76

SP - 443

EP - 449

JO - European Urology

JF - European Urology

IS - 4

ER -

Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this